← Back to Search

Floatation Therapy for Anorexia

N/A

Waitlist Available

Led By Sahib Khalsa, MD, PhD

Research Sponsored by Laureate Institute for Brain Research, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Primary clinical diagnosis of anorexia nervosa

Receiving inpatient treatment for eating disorder

Must not have

Active suicidal ideation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial will study the effects of Floatation-REST on symptoms of anorexia nervosa.

Who is the study for?

This trial is for individuals with anorexia nervosa who are currently in inpatient treatment, can walk on their own, haven't started new meds recently, and can lay flat without discomfort. They must have a BMI of at least 16 and be able to use a smartphone with internet. People with severe depression, self-harm behaviors, certain blood pressure issues or psychotic disorders cannot join.

What is being tested?

The study is examining the impact of Floatation-REST therapy combined with usual care versus usual care alone on anorexia nervosa symptoms. Participants will either continue their regular treatment or receive additional sessions of Floatation-REST where they'll experience reduced environmental stimulation.

What are the potential side effects?

While not explicitly stated here, potential side effects from Floatation-REST may include dizziness or nausea due to the sensory deprivation environment; however, these are generally mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition is diagnosed as anorexia nervosa.

Select...

I am currently hospitalized for an eating disorder treatment.

Select...

I can walk on my own without help.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently having thoughts about harming myself.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Body image dissatisfaction score on the Photographic Figure Rating Scale

Secondary study objectives

Anxiety on the NIH Promis Anxiety Scale

Anxiety on the Spielberger State Trait Anxiety Inventory

Anxiety sensitivity on the Anxiety Sensitivity Index-3R

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Usual careExperimental Treatment1 Intervention

Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.

Group II: Floatation-RESTExperimental Treatment1 Intervention

Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Usual care

2011

Completed Phase 4

~23770

0 / 4Eligibility criteria met